INTRODUCTION
Chylothorax is a rare potentially life-threatening condition characterized by the accumulation of chyle in the pleural space. It can be responsible for metabolic, nutritional and immunological complications, as well as respiratory distress in newborn infants. The diagnosis of chylothorax is usually based on a pleural effusion characterized by a triglyceride level > 110 mg/dL and a cell count > 1000/µL with > 80% lymphocytes.
1,2 Without enteral fat intake, the distinction between chylous and non-chylous effusion is difficult because chylomicrons are absent from the pleural fluid. In non-feeding infants, the diagnosis of chylothorax is made through the identification of a high number of lymphocytes in the serous fluid. 2, 3 Chylothorax can be congenital or acquired. Congenital chylothorax is the most common type of pleural effusion during the neonatal period, with an estimated incidence of 1:7300-1:15 000 and a male/female ratio of 2:1.
1-5
The etiology of congenital chylothorax is often unclear. Association with congenital heart disease, chromosomal disorders (e.g. Down, Turner or Noonan syndromes), prenatal infections, birth trauma, superior vena cava thrombosis and abnormalities of the lymphatic system are described. 1, 4, 6 Most cases have no clear etiology and are considered as idiopathic congenital chylothorax. 2 Acquired chylothorax is most often a postoperative complication due to trauma to the thoracic duct during cardiac or thoracic surgery. [4] [5] [6] [7] Management practices are not standardized and vary among neonatal units, from conservative approach (diet modifications and positive end expiratory pressure during mechanical ventilation) to medical (somatostin or octreotide) or surgical intervention (thoracoscopic pleurodesis, pleuroperitoneal shunt, surgical abrasion and ligation of the thoracic duct). 2, 7 None of these therapeutic modalities have undergone controlled clinical trials. 7 This study is a retrospective review of all cases of neonatal chylothorax admitted to a Portuguese perinatal unit and aimed to evaluate its course and treatment. Our unit provides tertiary level care for extremely premature infants and newborn infants with congenital heart disease.
METHODS
We carried out a retrospective review of our institutional records of newborn diagnosed with chylothorax between 1 st of February 2007 and 31 st of January 2017 in a tertiary neonatal intensive care unit. The following variables were evaluated: gender, gestational age, delivery mode, birth weight, Apgar score, etiology, age at diagnosis, associated pathologies, composition of pleural effusion, medical and surgical therapeutic and its complications. The inclusion criteria was the presence in a newborn of a pleural effusion characterized by > 1000 cells/µL with > 80% of lymphocytes and triglycerides greater than 110 mg/dL if they were on enteral feeding; while in non-feeding infants we used only the identification of a high number of lymphocytes (> 80%). Descriptive statistics were performed using Microsoft Excel ® .
RESULTS
Six patients were included. Demographic data are summarized in Table 1 .
Two cases (A and B) were congenital albeit only case A had a prenatal diagnosis at 21 weeks of gestational age, and no in utero intervention was needed. Case B, also congenital, was diagnosed during coarctation of the aorta repair surgery. Pleural effusions in congenital cases A and B were left sided and bilateral, respectively. Diagnosis was confirmed by cytochemical analysis of the pleural fluid, in which both had more than 80% lymphocytes. Case B had a triglyceride level > 110 mg/dL, however, case A had a lower value (19.2 mg/dL), because effusion drainage was performed on the first day of life before starting enteral nutrition ( Table 2 ). In case A, a thoracentesis was performed at day 1 with resolution of the effusion. Due to high-volume and persistence, case B was managed by drainage and subsequent insertion of a thoracic drain. Both cases needed ventilation support with high positive end-expiratory pressure (Table 3) . Congenital cases started parenteral nutrition at diagnosis. General measures, including adequate fluid and electrolyte replacement along with appropriate nutrition, permitted the resolution of case A. Case B did not respond to conservative treatment. In the context of diaphragmatic paralysis, we opted for the surgical intervention in the first place and a thoracic duct ligation was performed at day 43 of life. Recurrence of effusion occurred postoperatively and by day 50 octreotide was initiated for the following two weeks. As there was no improvement in the volume of the effusion as well as in the clinical status, the patient underwent right and left thoracoscopic talc pleurodesis at days 102 and 115 of life, respectively. Despite the multiple interventions, the patient died at 7 months with respiratory failure.
Remaining cases (C, D, E and F) were all secondary to trauma after thoracic surgery, three were on the left side corresponding to the intervened side and one was bilateral (case C). Diagnosis was made between day 7 and 20 postoperatively at the onset of symptoms of respiratory distress. Diagnosis was confirmed by cytochemical analysis of the pleural fluid (Table 2) , in all cases lymphocytes were more than 80% of all cells and triglyceride levels > 110 mg/dL. Due to high-volume and persistence, all patients with postoperative effusion were managed by drainage and subsequent insertion of a thoracic drain. All cases needed ventilation support with high positive end-expiratory pressure (Table 3 ). Regarding nutrition, cases C and D initiated parenteral nutrition and cases E and F remained on enteral feeding without longchain polyunsaturated fatty acids, with progressive medium-chain triglycerides supplementation. In cases secondary to trauma, general measures were effective in cases E and F. Cases C and D were treated with octreotide, with an initial dose of 1 µg/kg/h, up to a maximum of 10 µg/kg/h, although only case D was efficiently managed. Case C died due to persistent chylothorax, pulmonary hypertension, shock and multiorgan failure, on day 31 (Table 3) .
Hypoalbuminemia was the most frequent complication. In case A, the most severe, the minimum value of hypoalbuminemia was 1.7 g/dL.
Regarding the long-term outcomes, no data are available because two patients were transferred to their local hospitals after clinical stability and cases D and E have been followed in pediatric cardiology, without sequelae related to chylothorax. 
DISCUSSION
In our series, the traumatic cause -thoracic surgerywas the main etiology, reflecting our Unit´s collaboration with the pediatric cardiology department.
Concerning treatment, namely the relief of respiratory symptoms, the use of positive end-expiratory pressure ventilation is advised as it may tamponade the injured duct, helping to decrease chyle flow. 8, 9 Dietary measures are a mainstay in the treatment of chylothorax. Using a fat-free diet without long-chain fatty acids but supplemented with medium-chain triglycerides (MCT's), reduces lymphatic drainage because MCT's are absorbed directly into the portal venous system, bypassing the lymphatic system. 4, 10, 11 Cases that do not respond to a low-fat diet, as described above, might need parenteral nutrition with total enteric rest. Nevertheless, the risks associated with the use of a central venous catheterization in immunodeficient patients should be considered. [12] [13] [14] One of the main complications of chylothorax is secondary immunodeficiency, due to the loss of lymphocytes and immunoglobulins. In a group of 16 pediatric cardiac patients with postoperative chylothorax, there were B-cell and T-cell lymphopenia with a proportional decline of CD4+ and CD8+ cells. 15 Chyle also contains a high concentration of immunoglobulin and there are reports showing that persisting chyle losses can lead to hypogammaglobulinemia. 16, 17 One study reported that four out of seven (57%) patients with congenital chylothorax developed nosocomial infections, this incidence of nosocomial infections is about three times higher than that in other neonatal patients. 18 In a recent study, regardless of the heterogeneity of published reports, conservative management is appropriate as initial treatment for neonatal postsurgical chylothorax. 19 Observational studies suggest that octreotide should be considered in the conservative treatment of chylothorax when other conservative measures were not fruitful. Bellini et al concluded in a recent systematic review that octreotide is a relatively effective and safe treatment option in neonates with chylothorax. 20 Nevertheless, there are no firm recommendations concerning the timing and duration of this therapy. 2, [12] [13] [14] In our series, three patients were treated with octreotide: case C died two days after beginning due to shock and multiorgan failure, case D got better with this therapy (two weeks duration) and congenital case B did not improve at all. No side effects were registered.
Concerning surgical management of chylothorax, most studies recommend surgery if the effusion persists for more than three or four weeks despite conservative management. Surgery may, nevertheless, be anticipated if the effusion volume is persistently high despite drainage or if there are severe metabolic or nutritional complications. 4, 13, 21 In cases that require surgical management, thoracoscopic approach should be considered. 19 
CONCLUSION
This is a small study which reflects the rarity of this pathology, and it would be helpful a multicenter study to increase the number of patients assessed. Concerning diagnosis and treatment there are some algorithms, however, there are no national or international accepted guidelines and there are some aspects of the therapeutic approach that remain controversial, namely the heterogeneity in dosing regimens, mode of administration, therapeutic duration and time to start medical therapy [22] [23] [24] as well as the indications and timing for surgery. 6 
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